Correlates of Protection

Navigation Menu

General issues of Vaccine
Cold chain Correlates of Protection Vaccines for Asplenia Vaccines for Pregnant women Vaccines for Immunocompromised hosts Vaccine hesitancy Additional materials of vaccine

General issues of Tropical med.

Definition of Tropical Medicine Matrices of tropical infection General issues of Helminths Neglected Tropical Diseases Sexually-transmitted infections Non-Communicable Diseases Maternal health and contraception Child health Malnutrition and Micronutrient Eosinophilia Fever in the tropics Diarrhea in the tropics Anemia in the tropics Dermatology in the tropics Ophthalmology in the tropics Neurology in the tropics Mental health in the tropics Surgery in the tropics Humanitarian emergency Epidemiology in outbreak Antimicrobial resistance Pathology of infectious diseases

General issues of Travel med.
Epidemiology of Travel health Last minute traveler Time zone issue High altitude medicine Diving medicine Pregnancy and travel Children and travel Elderly and travel

Immunology
Principle of human immune system Innate immunity Cellular immunity Humoral immunity Neutralizing antibody and its assay Antigenic Cartography Additional materials of immunology

Epi & Stats
Basics & Definition Epidemiology Odds in statistics and Odds in a horse race Collider bias Data distribution Statistical test Regression model Multivariate analysis Marginal effects Prediction and decision Table-related commands in STATA Missing data and imputation

Virus
HIV HIV-TB co-infection HIV-STI interaction Viral Hemorrhagic Fever Ebola Crimean-Congo hemorrhagic fever SFTS Rabies Polio Dengue Yellow fever Chikungunya Zika Japanese encephalitis Tick-borne encephalitis Viral hepatitis Measles Smallpox and Monkeypox Respiratory Syncytial virus

COVID-19
Bivalent BA.1/BA.4-5 mRNA vaccines Monovalent XBB-1.5 mRNA vaccine Private archives of the initial phase of the pandemic Private archives of lecture materials of COVID vaccine as of March 2021 厚生労働省が発出する保健行政関連の文書の読み解き方

Bacteria
Bacteriological tests Tuberculosis Tuberculosis in Children HIV-TB co-infection Leprosy Dermatological mycobacterium infecions Syphilis and Yaws Plague Pneumococcus Meningococcus Typhoid Salmonellosis Melioidosis Leptospirosis Brucellosis Bartonellosis Lyme disease and Relapsing fever Tularaemia Tetanus Diphtheria Anthrax Coxiellosis

Rickettsia
Rickettsiosis Scrub typhus Spotted fevers Epidemic typhus Murine typhus

Protozoa
Overview of protozoa Overview of medicine for protozoa Malaria Chagas disease African trypanosomiasis Leishmaniasis Trichomoniasis Toxoplasmosis Amoebiasis Giardiasis Cryptosporidiosis Cyclosporiasis Isosporiasis Pentatrichomoniasis Microsporidiasis Babesiosis

Fungi
General issues of fungi Coccidioidomycosis Paracoccidioidomycosis Histoplasmosis Talaromycosis Blastomycosis Sporotrichosis

Nematode (roundworm)
Nematode principles Lympatic filariasis Onchocerciasis Loiasis Microscopic differentiation of microfilariae Strongyloidiasis Ascariasis Ancylostomiasis (hookworm) Trichuriasis (whipworm) Enterobiasis (pinworm) Angiostrongyliasis (rat lungworm) Dracunculiasis (Guinea worm) Anisakiasis Trichinellosis (Trichinosis) Gnathostomiasis Spirurinasis Soil-transmitted helminths

Trematode (fluke, distoma)
General issues of Helminths Trematode principles Schistosomiasis Clonorchiasis Fascioliasis Paragonimiasis Metagonimiasis

Cestode (tapeworm)
General issues of Helminths Cestode principles Diphyllobothriasis Sparganosis Taeniasis Echinococcosis

Medical Zoology
Zoonosis Insectology Mosquitology Acarology Batology Snake toxicology Scorpion and spider toxicology Marine toxicology

Correlates of Protection

Definitions of terms

Correlates of Protection (CoP)	An immune response statistically correlated with protection
Mechanistic CoP (mCoP)	An immune response responsible for protection
Non-mechanistic CoP (nCoP)	An immune response surrogating mCoP and easily measured

Identifying method of CoP (mCoP)

• Theoretically
  • To measure immune responses at the time of exposure to the infection and compare them between those who get infection and not
    • might be feasible by detecting immune responses of bloods donated just before an outbreak
• Practically
  • To measure immune responses after the vaccination and compare them between those who get infection and not
    • usually done in vaccine clinical trial phase 3
  • To measure immune responses at the time of challenging exposure of vaccinated volunteers
    • would be ethically approved only for milder and/or treatable infections such as seasonal influenza, cholera, dengue or cytomegalovirus
  • To extrapolate vaccinated animal challenge model
  • To extrapolate protective level of dosing of passive immunization (antibody treatment)

Be careful

• "Immune reseponses" contain various kinds of immunological functions, thus a single immune biomarker cannot necessarily be CoP
  • Serum antibodies with multiple isotypes and multiple functions
  • Mucosal antibodies with multiple isotypes and multiple functions
  • Helper T cells
  • Killer T cells
  • Regulatory T cells
  • Natural killer cells
  • Phagocytes and antigen-presenting cells
  • etc.
• Protection against infection is generally different from protection against disease
  • You should focus on which type of protection you expect

	Protection against infection	Protection against disease
Polio	Infection is prevented by mucosal antibodies at nasopharynx and intestine (IgA + diffused IgG)	Disease (paralysis) is prevented by serum antibodies before entering CNS via blood
Pneumococcus	Infection (bacteremia) is prevented by 0.20-0.35 µg/mL (ELISA) of serum antibodies	Disease (pneumonia, otitis media, nasopharynx carriage) is prevented by >10 times higher serum antibodies

An example of measles

Chen, R. T., Markowitz, L. E., Albrecht, P., Stewart, J. A., Mofenson, L. M., Preblud, S. R., & Orenstein, W. A. (1990). Measles Antibody: Reevaluation of Protective Titers. In The Journal of Infectious Diseases (Vol. 162). https://doi.org/10.1093/infdis/162.5.1036

Comparison between Cases and Non-cases; serologically confirmed

	Pre-exposure PRN ≤120 (GMT)	Pre-exposure PRN >120 (GMT)
Cases	8 cases (63)	0 case
Non-cases	1 non-case (56)	71 non-cases (1157)

*PRN = Plaque Reduction Neutralization

t test p<0.001

Comparison among serologically discarded Non-cases

	Pre-exposure PRN 216-874	Pre-exposure PRN ≥1052
Post-exposure PRN boosted†	7 non-cases	0 non-case
Post-exposure PRN unchanged	4 non-cases	7 non-cases

†suggestive of subclinical infection

Fisher's exact test p<0.001

Comparison among serologically discarded Non-cases

	Pre-exposure PRN <1052	Pre-exposure PRN ≥1052
Non-cases with ≥1 symptom‡	26 non-cases	11 non-cases
Non-cases with no symptom	11 non-cases	24 non-cases

‡suggestive of subclinical infection

χ² test p<0.002

Comparison between Cases and Non-cases; serologically confirmed

	Pre-exposure PRN ≤120	Pre-exposure PRN 121-1051	Pre-exposure PRN ≥1052
Cases with no vaccine	1 unvaccinated case
Cases with 1 vaccine	7 unvaccinated case
Non-cases with no vaccine		0 unvaccinated non-case	0 unvaccinated non-case
Non-cases with 1 vaccine		36 vaccinated non-cases	35 vaccinated non-cases

• Single definitive cut-off of CoP is not commonly available and CoP is generally relative
  • Generally speaking, the higher a CoP biomarker is, the more highly the subject is protected from infection or disease
  • In other words, a certain proportion of subjects with a certain level of CoP biomarker can be protected from infection/disease
    • The proportion of protected subjects increases as the level of CoP biomarker rises